Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock (MaxSep)

This study has been completed.
Sponsor:
Collaborators:
AstraZeneca
Bayer
Information provided by (Responsible Party):
Kompetenznetz Sepsis
ClinicalTrials.gov Identifier:
NCT00534287
First received: September 21, 2007
Last updated: June 28, 2012
Last verified: June 2012